Literature DB >> 10628831

Antibody response of patients infected with verocytotoxin-producing Escherichia coli to protein antigens encoded on the LEE locus.

C Jenkins1, H Chart, H R Smith, E L Hartland, M Batchelor, R M Delahay, G Dougan, G Frankel.   

Abstract

Sera from patients infected with verocytotoxin-producing Escherichia coli (VTEC) O157, from patients with antibodies to E. coli O157 lipopolysaccharide (LPS) and from healthy controls were examined for antibodies to proteins involved in expressing the attaching and effacing phenotype. After SDS-PAGE, purified recombinant intimin, EspA-filament structural protein, translocated protein EspB and three separate domains of the translocated intimin receptor (Tir) were tested for reaction with patients' sera by immunoblotting. An ELISA was also used to detect antibodies to intimin in sera from E. coli O157 LPS antibody-positive individuals. Seven of nine culture-positive patients and one control patient had antibodies to EspA. Five of these patients and two controls had serum antibodies to the intimin-binding region of Tir, whereas none of the sera contained antibodies binding to either of the intracellular domains of Tir. By immunoblotting, 10 of 14 culture-positive patients had antibodies to the conserved region of intimin, eight of whom were infected with E. coli O157 phage type 2. Thirty-six of 60 sera from culture-negative but E. coli O157 LPS antibody-positive patients had antibodies to intimin as determined by ELISA. The secreted proteins are expressed in vivo during infection and are considered as pathogenic markers. Antibodies to these proteins may form the basis of a serodiagnostic test for the detection of patients infected with VTEC which carry the locus for the enterocyte effacement pathogenicity island and provide an adjunct test to the established serological tests based on VTEC LPS.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10628831     DOI: 10.1099/0022-1317-49-1-97

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  19 in total

1.  Intestinal damage in enterohemorrhagic Escherichia coli infection.

Authors:  Zivile D Békássy; Carla Calderon Toledo; Gustav Leoj; Anncharlotte Kristoffersson; Shana R Leopold; Maria-Thereza Perez; Diana Karpman
Journal:  Pediatr Nephrol       Date:  2010-09-01       Impact factor: 3.714

2.  Immunoproteomic analysis to identify Shiga toxin-producing Escherichia coli outer membrane proteins expressed during human infection.

Authors:  David Montero; Paz Orellana; Daniela Gutiérrez; Daniela Araya; Juan Carlos Salazar; Valeria Prado; Angel Oñate; Felipe Del Canto; Roberto Vidal
Journal:  Infect Immun       Date:  2014-08-25       Impact factor: 3.441

3.  Humoral Immunity in the Gut Selectively Targets Phenotypically Virulent Attaching-and-Effacing Bacteria for Intraluminal Elimination.

Authors:  Nobuhiko Kamada; Kei Sakamoto; Sang-Uk Seo; Melody Y Zeng; Yun-Gi Kim; Marilia Cascalho; Bruce A Vallance; José L Puente; Gabriel Núñez
Journal:  Cell Host Microbe       Date:  2015-04-30       Impact factor: 21.023

Review 4.  Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni.

Authors:  Miguel O'Ryan; Roberto Vidal; Felipe del Canto; Juan Carlos Salazar; David Montero
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  EHEC Adhesins.

Authors:  Brian D McWilliams; Alfredo G Torres
Journal:  Microbiol Spectr       Date:  2014

6.  Intimin type influences the site of human intestinal mucosal colonisation by enterohaemorrhagic Escherichia coli O157:H7.

Authors:  R J Fitzhenry; D J Pickard; E L Hartland; S Reece; G Dougan; A D Phillips; G Frankel
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

7.  Intimin-specific immune responses prevent bacterial colonization by the attaching-effacing pathogen Citrobacter rodentium.

Authors:  M Ghaem-Maghami; C P Simmons; S Daniell; M Pizza; D Lewis; G Frankel; G Dougan
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

Review 8.  Advances in the development of enterohemorrhagic Escherichia coli vaccines using murine models of infection.

Authors:  Victor A Garcia-Angulo; Anjana Kalita; Alfredo G Torres
Journal:  Vaccine       Date:  2013-05-22       Impact factor: 3.641

9.  HEp-2 cell adherence, actin aggregation, and intimin types of attaching and effacing Escherichia coli strains isolated from healthy infants in Germany and Australia.

Authors:  Lothar Beutin; Olivier Marchés; Karl A Bettelheim; Kerstin Gleier; Sonja Zimmermann; Herbert Schmidt; Eric Oswald
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

10.  Human milk secretory antibodies against attaching and effacing Escherichia coli antigens.

Authors:  Marita Noguera-Obenza; Theresa J Ochoa; Henry F Gomez; M Lourdes Guerrero; Irene Herrera-Insua; Ardythe L Morrow; Guillermo Ruiz-Palacios; Larry K Pickering; Carlos A Guzman; Thomas G Cleary
Journal:  Emerg Infect Dis       Date:  2003-05       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.